

FINAL EXAM
DECEMBER 2019

www.FirstRanker.com

www.FirstRanker.com

NATIONAL BOARD OF EXAMINATIONS

RADIOTHERAPY PAPER-IV

Time: 3 hours Max. Marks: 100 RTH/D/19/41/IV

Important Instructions:

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space.
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

- 1. a) Describe in detail the cell cycle.b) Describe the mechanisms of DNA repair.
- 2. Discuss the GEC-ESTRO guidelines in practice. How does it differ 5+5 from the previously used systems?
- 3. a) What is meant by Therapeutic Ratio and Therapeutic Window? 2+4+4
 - b) Describe the chemical means of modifying the Therapeutic Ratio and Therapeutic Window.
 - c) Describe the physical means of modifying the Therapeutic Ratio and Therapeutic Window.
- 4. a) Discuss the basis of immunotherapy. 4+3+3
 - b) Name the major types of immunotherapy.
 - c) Evidence to support the use of RT to promote immune mediated killing of an irradiated tumour.
- 5. a) TACE. 2+2+2+2
 - b) EBUS.
 - c) Tumour markers in cancer management.
 - d) Screening for Breast Cancer.
 - e) Photodynamic therapy.
- 6. Discuss the role of Total Body Irradiation as part of patients 10 undergoing stem cell transplantation including indications, techniques and dose schedules.
- 7. a) What is FLASH Radiotherapy? 5+5
 - b) Biological benefits of FLASH-RT.

P.T.O



www.FirstRanker.comational Bwww.FirstRanker.com

RADIOTHERAPY PAPER-IV

8.	Discuss errors in Radiotherapy with respect to: a) Commission and Omission. b) Measure for reduction of these errors.	5+5
9.	a) Multileaf Collimators.b) Inverse Planning.c) Gated Radiotherapy.d) Virtual Simulation.	2.5x4
10.	a) Immunohistochemistry in cancer management.b) Tumour angiogenesis.c) Triple phase scan for hepatic lesions.d) EGFR.	2.5x4